HR22C16

structure in first source

Networked: 1 relevant articles (0 outcomes, 0 trials/studies)

1.	Garrett, Sarah: 1 article (03/2005)
2.	Giannakakou, Paraskevi: 1 article (03/2005)
3.	Kapoor, Tarun M: 1 article (03/2005)
4.	Marcus, Adam I: 1 article (03/2005)
5.	Peters, Ulf: 1 article (03/2005)
6.	Thomas, Shala L: 1 article (03/2005)
7.	Zelnak, Amelia: 1 article (03/2005)

1.	Ovarian Neoplasms (Ovarian Cancer) 03/25/2005 - "Furthermore, HR22C16 along with its analogs, inhibit cell survival in both Taxol-sensitive and -resistant ovarian cancer cells with at least 15-fold greater efficacy than monastrol, the first generation Eg5 inhibitor. "